Ersilia Satta
Research Subjects
Ersilia Satta has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Fucili
Cardiovascular Research Center, Ferrara University, Ferrara, Italy
1 shared publication - Felice Strollo
Endocrinology Department, IRCCS San Raffaele Pisana, 00163 Roma, Italy
1 shared publication - Francesca Porcellati
Department of Medicine and Surgery, Perugia University Medical School, 06126 Perugia, Italy
1 shared publication - Marcello Monesi
UOC (Unità Operativa Complessa) Territorial Diabetology, AUSL Ferrara, 44121 Ferrara, Italy
1 shared publication - Sandro Gentile
Campania University "Luigi Vanvitelli", Naples, Italy; Nefrocenter Research Network & Nyx Research Start-Up, Naples, Italy
1 shared publication - Vincenzo Maria Monda
Diabetes Unit “Santissima Annunziata” Hospital Cento, Ferrara, Italy
1 shared publication
Latest Publications
- Open Access
- 17 July 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (8) , 4195-4214
Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control as well as chronic heart failure and kidney disease prevention.
- 17 July 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (8) , 4195-4214
Open AccessPossible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control as well as chronic heart failure and kidney disease prevention.